Cargando…

Enhancing immunotherapy response in melanoma: myeloid-derived suppressor cells as a therapeutic target

Despite the remarkable success of immune checkpoint inhibitors (ICIs) in melanoma treatment, resistance to them remains a substantial clinical challenge. Myeloid-derived suppressor cells (MDSCs) represent a heterogeneous population of myeloid cells that can suppress antitumor immune responses mediat...

Descripción completa

Detalles Bibliográficos
Autores principales: Ozbay Kurt, Feyza Gul, Lasser, Samantha, Arkhypov, Ihor, Utikal, Jochen, Umansky, Viktor
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Clinical Investigation 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10313369/
https://www.ncbi.nlm.nih.gov/pubmed/37395271
http://dx.doi.org/10.1172/JCI170762
_version_ 1785067112098693120
author Ozbay Kurt, Feyza Gul
Lasser, Samantha
Arkhypov, Ihor
Utikal, Jochen
Umansky, Viktor
author_facet Ozbay Kurt, Feyza Gul
Lasser, Samantha
Arkhypov, Ihor
Utikal, Jochen
Umansky, Viktor
author_sort Ozbay Kurt, Feyza Gul
collection PubMed
description Despite the remarkable success of immune checkpoint inhibitors (ICIs) in melanoma treatment, resistance to them remains a substantial clinical challenge. Myeloid-derived suppressor cells (MDSCs) represent a heterogeneous population of myeloid cells that can suppress antitumor immune responses mediated by T and natural killer cells and promote tumor growth. They are major contributors to ICI resistance and play a crucial role in creating an immunosuppressive tumor microenvironment. Therefore, targeting MDSCs is considered a promising strategy to improve the therapeutic efficacy of ICIs. This Review describes the mechanism of MDSC-mediated immune suppression, preclinical and clinical studies on MDSC targeting, and potential strategies for inhibiting MDSC functions to improve melanoma immunotherapy.
format Online
Article
Text
id pubmed-10313369
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher American Society for Clinical Investigation
record_format MEDLINE/PubMed
spelling pubmed-103133692023-07-03 Enhancing immunotherapy response in melanoma: myeloid-derived suppressor cells as a therapeutic target Ozbay Kurt, Feyza Gul Lasser, Samantha Arkhypov, Ihor Utikal, Jochen Umansky, Viktor J Clin Invest Review Despite the remarkable success of immune checkpoint inhibitors (ICIs) in melanoma treatment, resistance to them remains a substantial clinical challenge. Myeloid-derived suppressor cells (MDSCs) represent a heterogeneous population of myeloid cells that can suppress antitumor immune responses mediated by T and natural killer cells and promote tumor growth. They are major contributors to ICI resistance and play a crucial role in creating an immunosuppressive tumor microenvironment. Therefore, targeting MDSCs is considered a promising strategy to improve the therapeutic efficacy of ICIs. This Review describes the mechanism of MDSC-mediated immune suppression, preclinical and clinical studies on MDSC targeting, and potential strategies for inhibiting MDSC functions to improve melanoma immunotherapy. American Society for Clinical Investigation 2023-07-03 /pmc/articles/PMC10313369/ /pubmed/37395271 http://dx.doi.org/10.1172/JCI170762 Text en © 2023 Ozbay Kurt et al. https://creativecommons.org/licenses/by/4.0/This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Review
Ozbay Kurt, Feyza Gul
Lasser, Samantha
Arkhypov, Ihor
Utikal, Jochen
Umansky, Viktor
Enhancing immunotherapy response in melanoma: myeloid-derived suppressor cells as a therapeutic target
title Enhancing immunotherapy response in melanoma: myeloid-derived suppressor cells as a therapeutic target
title_full Enhancing immunotherapy response in melanoma: myeloid-derived suppressor cells as a therapeutic target
title_fullStr Enhancing immunotherapy response in melanoma: myeloid-derived suppressor cells as a therapeutic target
title_full_unstemmed Enhancing immunotherapy response in melanoma: myeloid-derived suppressor cells as a therapeutic target
title_short Enhancing immunotherapy response in melanoma: myeloid-derived suppressor cells as a therapeutic target
title_sort enhancing immunotherapy response in melanoma: myeloid-derived suppressor cells as a therapeutic target
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10313369/
https://www.ncbi.nlm.nih.gov/pubmed/37395271
http://dx.doi.org/10.1172/JCI170762
work_keys_str_mv AT ozbaykurtfeyzagul enhancingimmunotherapyresponseinmelanomamyeloidderivedsuppressorcellsasatherapeutictarget
AT lassersamantha enhancingimmunotherapyresponseinmelanomamyeloidderivedsuppressorcellsasatherapeutictarget
AT arkhypovihor enhancingimmunotherapyresponseinmelanomamyeloidderivedsuppressorcellsasatherapeutictarget
AT utikaljochen enhancingimmunotherapyresponseinmelanomamyeloidderivedsuppressorcellsasatherapeutictarget
AT umanskyviktor enhancingimmunotherapyresponseinmelanomamyeloidderivedsuppressorcellsasatherapeutictarget